Antibacterial and leishmanicidal activities of temporin-SHd, a 17-residue long membrane-damaging peptide

Abbassi, Feten; Raja, Zahid; Oury, Bruno; Gazanion, Élodie; Piesse, Christophe; Sereno, Denis; Nicolas, Pierre; Foulon, Thierry; Ladram, Ali

doi:10.1016/j.biochi.2012.10.015

Cited by 50 publications

(80 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[7][8][9][10] Despite the fact that temporins are mainly active against Gram-positive bacteria, a few peptides, such as temporin-Tl (net charge = +3), temporin-DRa (+3), temporin-SHa (+2) and temporin-SHd (+2), have broad-spectrum activity and also kill Gram-negative bacteria. [11][12][13] The two latter peptides also show potent activity against Leishmania with no cytotoxicity toward the host cell (macrophage) at leishmanicidal concentrations, making them, along with temporin-Ta, temporin-Tb, temporin-Tl, and temporin-Tf, the only members of the temporin family to display antiparasitic activity. [14][15][16] 4 Mechanistically, it is assumed that temporins insert into the hydrophobic core of the bacterial membrane and lead to membrane permeabilization and/or disruption according to a barrel-stave model or a detergent-like effect, depending on the peptide/lipid ratio.…”

Section: Introductionmentioning

confidence: 99%

Structure–Activity Relationship-based Optimization of Small Temporin-SHf Analogs with Potent Antibacterial Activity

et al. 2015

Self Cite

View full text Add to dashboard Cite

Short antimicrobial peptides represent attractive compounds for the development of new antibiotic agents. Previously, we identified an ultrashort hydrophobic and phenylalanine-rich peptide, called temporin-SHf, representing the smallest natural amphibian antimicrobial peptide known to date. Here, we report on the first structure-activity relationship study of this peptide. A series of temporin-SHf derivatives containing insertion of a basic arginine residue as well as residues containing neutral hydrophilic (serine and α-hydroxymethylserine) and hydrophobic (α-methyl phenylalanine and p-(t)butyl phenylalanine) groups were designed to improve the antimicrobial activity, and their α-helical structure was investigated by circular dichroism and nuclear magnetic resonance spectroscopy. Three compounds were found to display higher antimicrobial activity with the ability to disrupt (permeabilization/depolarization) the bacterial membrane while retaining the nontoxic character of the parent peptide toward rat erythrocytes and human cells (THP-1 derived macrophages and HEK-293). Antimicrobial assays were carried out to explore the influence of serum and physiological salt concentration on peptide activity. Analogs containing d-amino acid residues were also tested. Our study revealed that [p-(t)BuF(2), R(5)]SHf is an attractive ultrashort candidate that is highly potent (bactericidal) against Gram-positive bacteria (including multidrug resistant S. aureus) and against a wider range of clinically interesting Gram-negative bacteria than temporin-SHf, and also active at physiological salt concentrations and in 30% serum.

show abstract

Section: Introductionmentioning

confidence: 99%

Structure–Activity Relationship-based Optimization of Small Temporin-SHf Analogs with Potent Antibacterial Activity

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…promastigotes and amastigotes, T. cruzi epimastigotes, and T. brucei gambiense procyclic forms -with IC 50 values ranging between 6.7 and 23.5 mM. At these concentration values, cytotoxicity (towards erythrocytes and macrophages) was either low or absent (Abbassi et al 2013). Drug Discovery DOI 10.1007/978-94-007-6726-3_4-1 # Springer Science+Business Media Dordrecht 2015 Magainins and PGLa Magainins are 23-amino-acid peptides first isolated from the skin of the African clawed frog Xenopus laevis and belonging to the large family of amphibian amphipathic and a-helical antimicrobial peptides (Zairi et al 2009;Zasloff 1987).…”

Section: Temporinsmentioning

confidence: 98%

“…Temporins constitute a large family of a-helical AMPs produced by the skin of Eurasian and New World ranid frogs (Abbassi et al 2013;Mangoni et al 2000a). They are short, 8-17-amino-acid peptides, amidated at the C-terminus and with a low net positive charge (from 0 to +3, with only one positively charged amino acid).…”

Section: Temporinsmentioning

confidence: 99%

“…Temporins display activity against viruses, Gram-positive bacteria (including vancomycin-resistant Enterococcus faecium and E. faecalis) and methicillin-resistant Staphylococcus aureus, with MICs ranging from 2.5 to 25 mM (Chinchar et al 2004;Conlon et al 2006;Giacometti et al 2005). However, only a few temporins with a net charge of +3 are active against Gramnegative bacteria, fungi and yeasts (Abbassi et al 2008(Abbassi et al , 2013Conlon et al 2006;Rollins-Smith et al 2003). A common feature of temporins is the absence (or near absence) of toxicity to mammalian cells (Abbassi et al 2008(Abbassi et al , 2013Conlon et al 2007;Mangoni et al 2005).…”

Section: Temporinsmentioning

confidence: 99%

“…However, only a few temporins with a net charge of +3 are active against Gramnegative bacteria, fungi and yeasts (Abbassi et al 2008(Abbassi et al , 2013Conlon et al 2006;Rollins-Smith et al 2003). A common feature of temporins is the absence (or near absence) of toxicity to mammalian cells (Abbassi et al 2008(Abbassi et al , 2013Conlon et al 2007;Mangoni et al 2005).…”

Section: Temporinsmentioning

confidence: 99%

See 2 more Smart Citations

Venoms as Sources of Novel Anti-parasitic Agents

Adade

Souto-Padrón

2015

Toxins and Drug Discovery

View full text Add to dashboard Cite

Parasitic diseases continue to take an enormous toll on human health, particularly in developing tropical regions, where more than 200 millions people are infected with protozoan parasites belonging to the genera Plasmodium, Trypanosoma, and Leishmania, responsible for Malaria, African trypanosomiasis, and Chagas disease, and the different forms of leishmaniasis. Current antiprotozoan chemotherapeutic agents are toxic and have many decades of clinical use, with ever decreasing efficacy due to drug resistance. Therefore, there is an urgent need for the development of novel agents against protozoan parasites. In recent years, research into animal venom toxins and other molecules isolated from natural sources has intensified, focusing on the potential of these compounds to interfere with parasite physiology and/or vector biology. Venom components and their derivatives already represent more than 50 % of pharmaceuticals in clinical use, and novel drugs to treat parasitic diseases could be developed from these compounds. This chapter examines in detail the research into numerous animal venom toxins with potential to become novel clinical agents to treat protozoan-borne diseases. Also, some of these compounds are capable of inhibiting parasite establishment in the insect vector, representing good candidates to be used in the development of strategies for disease transmission control. Overall, the studies discussed here correspond to significant advances in the discovery of new antiprotozoan molecules, and highlight the potential of venoms and toxins as rich sources of relevant biologically active compounds.

show abstract

Emerging strategies and therapeutic innovations for combating drug resistance in Staphylococcus aureus strains: A comprehensive review

Gopikrishnan,

Haryini,

2024

J Basic Microbiol

View full text Add to dashboard Cite

In recent years, antibiotic therapy has encountered significant challenges due to the rapid emergence of multidrug resistance among bacteria responsible for life‐threatening illnesses, creating uncertainty about the future management of infectious diseases. The escalation of antimicrobial resistance in the post‐COVID era compared to the pre‐COVID era has raised global concern. The prevalence of nosocomial‐related infections, especially outbreaks of drug‐resistant strains of Staphylococcus aureus, have been reported worldwide, with India being a notable hotspot for such occurrences. Various virulence factors and mutations characterize nosocomial infections involving S. aureus. The lack of proper alternative treatments leading to increased drug resistance emphasizes the need to investigate and examine recent research to combat future pandemics. In the current genomics era, the application of advanced technologies such as next‐generation sequencing (NGS), machine learning (ML), and quantum computing (QC) for genomic analysis and resistance prediction has significantly increased the pace of diagnosing drug‐resistant pathogens and insights into genetic intricacies. Despite prompt diagnosis, the elimination of drug‐resistant infections remains unattainable in the absence of effective alternative therapies. Researchers are exploring various alternative therapeutic approaches, including phage therapy, antimicrobial peptides, photodynamic therapy, vaccines, host‐directed therapies, and more. The proposed review mainly focuses on the resistance journey of S. aureus over the past decade, detailing its resistance mechanisms, prevalence in the subcontinent, innovations in rapid diagnosis of the drug‐resistant strains, including the applicants of NGS and ML application along with QC, it helps to design alternative novel therapeutics approaches against S. aureus infection.

show abstract

Antibacterial and leishmanicidal activities of temporin-SHd, a 17-residue long membrane-damaging peptide

Cited by 50 publications

References 57 publications

Structure–Activity Relationship-based Optimization of Small Temporin-SHf Analogs with Potent Antibacterial Activity

Structure–Activity Relationship-based Optimization of Small Temporin-SHf Analogs with Potent Antibacterial Activity

Venoms as Sources of Novel Anti-parasitic Agents

Emerging strategies and therapeutic innovations for combating drug resistance in Staphylococcus aureus strains: A comprehensive review

Contact Info

Product

Resources

About